LY2584702

DRUG3 trials

Sponsors

Eli Lilly and Company

Conditions

Advanced CancerCancerCarcinoma, Non-small Cell LungMetastases, NeoplasmNeuroendocrine TumorsRenal Cell Carcinoma

Phase 1

A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors

TerminatedNCT01115803

Eli Lilly and CompanyCarcinoma, Non-small Cell Lung, Metastases, Neoplasm, Neuroendocrine Tumors +1

Start: 2010-03-31End: 2011-06-30Updated: 2019-02-05

A Study of LY2584702 in Solid Tumors

CompletedNCT01241461

Eli Lilly and CompanyCancer

Start: 2010-11-30End: 2011-11-30Updated: 2018-08-21

A Study of LY2584702 in Participants With Advanced Cancer

TerminatedNCT01394003

Eli Lilly and CompanyAdvanced Cancer

Start: 2008-11-30End: 2011-04-30Updated: 2019-01-18